Better and faster development: the regulators perspective on B/R assessment in orphan medicinal products
|
|
- Barry Evans
- 6 years ago
- Views:
Transcription
1 Better and faster development: the regulators perspective on B/R assessment in orphan medicinal products Violeta Stoyanova, MD, PhD, MPH COMP member NL Rare Disease Patient in 2030 March 30 th, 2017, Amsterdam
2 V. Stoyanova 2
3 How do Regulators work? Utrecht London V. Stoyanova 3
4 28 National Competent Authorities Responsible for expertise EU institutions: Commission Parliament Management Board Committee on Herbal Medicinal Products HMPC Committee for Advanced Therapies CAT Pharmacovigilance Risk Assessment Comittee PRAC V. Stoyanova EMA Secretariat Committee for Human Medicinal Products CHMP and WPs 4 Paediatric Committee PDCO Committee for Veterinary Medicinal Products CVMP Committee for Orphan Medicinal Products COMP
5 Stages and interactions with regulatory authorities CBG COMP CAT SAWP COMP PDCO CHMP CAT SAG PRAC V. Stoyanova 5
6 Application for orphan designation COMP Prevalence Seriousness Significant benefit SAWP EC Decision on designation (assumed) Protocol assistance Application for marketing authorisation Prevalence Seriousness COMP QSE Similarity Derogations CHMP Significant benefit (confirmed) COMP Opinion on maintenance orphan status CHMP opinion 6V. Stoyanova MARKETING AUTHORISATION
7 Why an orphan regulation? "Society cannot accept that certain individuals be denied the benefits of medical progress simply because the affliction from which they suffer affects only a small number of people. It is therefore up to the public authorities to provide the necessary incentives and to adapt their administrative procedures so as to make it as easy as possible to provide these patients with medicinal products which are just as safe and effective as any other medicinal products and meet the same quality standards. EU Charter of Fundamental Rights V. Stoyanova 7
8 23 February 1995, Expert group formed with the objective of discussing recommendations on priorities for EU level research and regulatory action in the field of rare diseases and orphan drugs 16 December 1999 V. Stoyanova 8 Adapted from PAMPLIN, College of Business Magazine, Virginia Tech, 2013
9 Principles on European orphan drug designation Main objectives of Regulation (EC) No 141/2000 Provide incentives that stimulate research and development Modify market conditions Set up system of recognition for orphan medicines to be eligible for incentives V. Stoyanova 9
10 The Committee for Orphan Medicinal Products Main items on the COMP agenda Orphan designation Protocol assistance Orphan status at time of marketing authorization Advising the EC on the establishment and development of a policy on OMP in the EU Assists the EC in drawing up detailed guidelines and liaising internationally on matters relating to OMP - Involvement with patient and consumers, academia, industry - Workshop on DMD - Workshop on SMA - EURORDIS summer school - World Orphan Drug Congress V. Stoyanova 10
11 COMP: The ODD procedure Publication of public summary of opinion (lay language) on EMA website V. Stoyanova 11
12 Criteria for orphan drug designation V. Stoyanova 12
13 Application for orphan designation COMP Prevalence Seriousness Significant benefit SAWP EC Decision on designation (assumed) Protocol assistance Application for marketing authorisation Prevalence Seriousness COMP QSE Similarity Derogations CHMP Significant benefit (confirmed) COMP Opinion on maintenance orphan status CHMP opinion 13 V. Stoyanova MARKETING AUTHORISATION
14 Scientific advice - EU standards EUROPE Requesting scientific advice from regulatory authorities is not mandatory but up to the company s free choice SAWP of CHMP - NCA s are represented on basis of expertise (not all 28 NCA s participate) NL is represented with 2 members and 2 alternates in SAWP MEMBER STATES At the National level, not all NCA s provide scientific advice, but the larger national authorities have it in place: e.g. NL, UK, DK, SE, DE, FR, ES, IT, PT, BE, AT V. Stoyanova 14
15 The impact of Scientific Advice / Protocol Assistance MAA success for MAAs with SA/PA submitted in Hofer et al., Nat Rev Drug Discov V. Stoyanova 15
16 Application for orphan designation COMP Prevalence Seriousness Significant benefit SAWP EC Decision on designation (assumed) Protocol assistance Application for marketing authorisation Prevalence Seriousness COMP QSE Similarity Derogations CHMP Significant benefit (confirmed) COMP Opinion on maintenance orphan status CHMP opinion 16 V. Stoyanova MARKETING AUTHORISATION
17 CHMP: the MAA procedure (Co)Rapporteurs Assessment Report Day 80 Primary Evaluation Phase Day 1 Comments Peer review dloq (other countries) CHMP List of Questions Day 120 Stop Clock Max. 6 months Day 121 Response to LoQ Start Clock Day 150 Joint Rapp./ Co-rapp. AR Hearing? Day 180 Stop Clock Hearin g Day 181 Start Clock Secondary Evaluation Phase SAG? Day 210 Adoption of Opinion 17 V. Stoyanova
18 The regulatory framework For each step in the procedure: guidelines! >450 guidelines To ensure quality of the product To get high quality data (GCP, GLP) To get sufficient nonclinical and clinical data To enable an adequate Benefit/risk assessment V. Stoyanova 18
19 Different Phases in Drug Development * Phase I * Phase II * Scientific Advice? Phase III Registration: Full Conditional SmPC Phase IV Follow-up measures? Initial safety, pharmacology in humans. therapeutic exploratory studies in selected patients (high risk pop.), well-monitored; dose & dose regimen determination. Confirmation of clinical efficacy and safety in target patient Population (surrogate & clinical endpoints) Studies after approval e.g. on therapeutic use, drug-drug interaction, large safety studies, epidemiological studies. V. Stoyanova 19
20 The B/R Balance The Assessment Team Quality assessors Efficacy Safety Pre-clinical assessors PK assessors Clinical assessors External experts (patient representative, medical specialists / hospital pharmacists) V. Stoyanova 20
21 Can the drug be approved based on the proposed SPC? Why was the drug developed? How was the drug tested? What were the results? What is the benefit/risk balance? V. Stoyanova 21
22 The critical evaluation of the individual study Aim: Confirmation of effect Effect size and relevance of effect Patient population Dose recommendations (long-term) Safety information V. Stoyanova 22
23 Internal validity A comparative trial has internal validity if, based on the methodology, it can be expected that the observed therapeutic effect is not biased by other differences in the group caused by: Differences in the natural history Randomisation Observational errors Blinding Non-specific external facors Introduce control groups Parallel (preferred) Cross-over (disadvantage carry over & unstable disease) V. Stoyanova 23
24 Patients Population should reflect the target population, including gender and age Broad or narrow population? Region (standard of care may differ) Internal validity homogenous External validity - generalisable Sometimes contradictory V. Stoyanova 24
25 Comparator No other medicine registered for the condition A need for placebo controlled trial? Other possible solutions? If one or more medicinal products are licensed for the condition: Still a need for placebo controlled trial? A need for an active control and placebo? When are historical controls a solution? What about ethics? How to assess benefit/risk? V. Stoyanova 25
26 Endpoints Primary endpoint To demonstrate an effect in the required indication Secondary endpoints To support the primary endpoint To support additional claims Type of endpoint Biomarker Surrogate endpoint Clinical endpoint Cave data fishing: handling of endpoints has to be defined in the study protocol a priori! V. Stoyanova 26
27 Assessment of benefits and risks Dependent on disease Minimum acceptable efficacy Maximum acceptable harm for patients Maximum acceptable harm for regulators Disapprove RM Zone Approve Maximum acceptable risk Minimum acceptable efficacy for patients Minimum acceptable efficacy for regulators V. Stoyanova 27 Julie Andrews, ICPE 2006
28 A marketing authorisation results in: Marketing Authorisation Advice to EC Approved in all EU/EEA countries SmPC (info for healthcare professionals) PIL (info for patient) EPAR: European Public Assessment Report Nota bene! The orphan status is reassessed at the time of MAA may be maintained or not. Not all products with an orphan designation will come to the EU market as OMPs. V. Stoyanova 28
29 Orphan Medicinal Products Facts and Figures V. Stoyanova 29
30 V. Stoyanova 30
31 Orphan Applications Figures submitted negative opinions positive opinions withdrawals during assessment EC Designations V. Stoyanova 31
32 The orphan status is not easy to obtain Total Applications submitted Positive COMP Opinions Negative COMP Opinions EC Designations Withdrawals during assessment V. Stoyanova 32
33 Orphan Designated Conditions % 18% 18% 25% 28% 14% 26% 16% 23% 21% 33% 39% 42% 44% 51% 78% NEW CONDITIONS (487) 27% TOTAL DESIGNATIONS (1805) V. Stoyanova 33
34 V. Stoyanova 34
35 V. Stoyanova 35
36 How are medicines approved? Centralised procedure, via EMA; National licence, Mutual recognition procedure, Decentralised procedure, via NCAs. V. Stoyanova 36
37 The way forward towards 2030? V. Stoyanova 37
38 Adaptive licensing opens a window for adanced observational studies, registries and pragmatic trials Eichler HG et al. Clin Pharmacol Ther 2012; 91: V. Stoyanova 38
39 V. Stoyanova 39
40 Innovative medicines faster available for the (Dutch) patient at a socially acceptable price V. Stoyanova 40
41 Different study methods/designs vs. types of conditions Adequate safety data Multi-arm designs and platform trial designs Decision analytic approaches and rational approaches to adjusting levels of evidence Extrapolation problems and opportunities Patients engagement in study design V. Stoyanova 41
42 Thank you! Working for more, better, faster and accessible treatments for rare diseases V. Stoyanova 42
Mandate, objectives and rules of procedure for the Inter- Committee Scientific Advisory Group (SAG) for Oncology
25 April 2014 EMA/742599/2014 Human Medicines Evaluation Division Mandate, objectives and rules of procedure for the Inter- Committee Scientific Advisory 1. Legal basis Article 56(2) of Parliament and
More informationThe PCWP will now collaborate with the Agency in the revision, implementation and monitoring of the framework of interaction.
30 May 2013 EMA/369907/2010 Rev. 2 Patient Health Protection Mandate, objectives and rules of procedure for the European Medicines Agency Human Scientific Committees Working Party with Patients' and Consumers'
More informationMandate, objectives and rules of procedure
12 September 2013 Compliance and Inspections Good Clinical Practice Inspectors Working Group (GCP IWG) 1. General considerations In 1997, the Ad Hoc Meeting of GCP Inspection Services was established by
More informationClinical Trials Innovation Programme October 22-23, 2015 Frankfurt, Germany Accell Clinical Research, LLC
New Russian Drug Law: Changes Concerning Clinical Studies and Marketing Authorization and Their Implications Dr. Natalia Nayanova Director, Clinical Operations Accell Clinical Research Clinical Trials
More informationAnalytical Fiche Nr 9. Scientific Committees
Analytical Fiche Nr 9 Scientific Committees 1) State of play de jure and in practice The constituent acts of five agencies 1 foresee the establishment of one Scientific Committee, while ECHA has two independent
More informationPharmacovigilance and Drug Safety: Practical Problems and Challenges Issues surrounding enforcement and sanctions including penalties regulations
Pharmacovigilance and Drug Safety: Practical Problems and Challenges Issues surrounding enforcement and sanctions including penalties regulations Pharmaceutical regulatory and compliance congress and best
More informationProcedure for the review and revision of European Union herbal monographs and European Union list entries
24 July 2018 EMA/HMPC/124695/2011 Rev. 2 Committee on Herbal Medicinal Products (HMPC) Procedure for the review and revision of European Union herbal monographs and European Union list entries Final Draft
More informationStandard operating procedure
Standard operating procedure Title: Annual reassessment of centrally authorised veterinary medicinal products under exceptional circumstances Status: PUBLIC Document no.: SOP/V/4006 Lead author Approver
More informationE U C O P E S y n o p s i s
E U C O P E S y n o p s i s Based on Regulation (EU) No 1235/2010 as published in the Official Journal of the European Union (L 348/1, 31.12.2010) Rue d Arlon 50 1000 Brussels www.eucope.org natz@eucope.org
More informationProcedure for the review and revision of European Union herbal monographs and European Union list entries
1 2 3 19 September 2017 EMA/HMPC/124695/2011 Rev. 2 Committee on Herbal Medicinal Products (HMPC) 4 5 6 Procedure for the review and revision of European Union herbal monographs and European Union list
More informationEuropean Medicines Agency Inspections
European Medicines Agency Inspections London, 27 July 2007 Doc. Ref.: EMEA/INS/GCP/239486/2007 MANDATE, OBJECTIVES AND RULES OF PROCEDURE FOR THE GCP INSPECTORS WORKING GROUP (GCP IWG) I. GENERAL CONSIDERATIONS
More informationEuropean Medicines Agency decision
EMA/757981/2016 European Medicines Agency decision P/0341/2016 of 5 December 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/498686/2017 European Medicines Agency decision P/0252/2017 of 4 September 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver
More informationProcedure for the systematic review of European Union herbal monographs and/or European Union list entries and supporting documents
28 January 2015 EMA/HMPC/124695/2011 Committee on Herbal Medicinal Products (HMPC) Procedure for the systematic review of European Union herbal monographs and/or European Union list entries and supporting
More informationEuropean Medicines Agency decision
EMA/380528/2016 European Medicines Agency decision P/0159/2016 of 15 June 2016 on the refusal of a modification of an agreed paediatric investigation plan for tafluprost (Taflotan and associated names)
More informationEuropean Medicines Agency decision
EMA/579489/2016 European Medicines Agency decision P/0234/2016 of 9 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole (EMEA-001185-PIP01-11-M03)
More informationD2 a copy of a Commission Decision of 22 January 2009 for a new oral formulation of COZAAR suitable for paediatric use.
Decision in Respect of an Application by E.I. Du Pont De Nemours & Company for the Grant of an Extension of Duration of the SPC No. 1996/028 for COZAAR 1. This decision relates to an application by E.I.
More informationAmended proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EUROPEAN COMMISSION Brussels, 11.10.2011 COM(2011) 633 final 2008/0256 (COD) Amended proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL Amending Directive 2001/83/EC, as regards information
More informationParallel Consultations
Parallel Consultations An overview of the procedure Presented by Jane Moseley on Senior Scientific Officer Scientific Advice Office An agency of the European Union Outline Parallel advice with HTAs Rationale
More informationPROCEDURAL ADVICE ON REPEAT-USE
PROCEDURAL ADVICE ON REPEAT-USE Doc. Ref.: CMDh/008/2009/Rev7 July 2011 1. INTRODUCTION A Marketing Authorisation Holder (MAH) can use the Mutual Recognition Procedure (MRP) for the same authorisation
More informationRecommendation for Mutual Recognition Procedure after finalisation of an article 34 referral procedure with a positive decision by the EC
13 October 2011 EMA/CMDv/422851/2009 Recommendation for Mutual Recognition Procedure after finalisation of an article 34 referral procedure with a positive decision by the EC 1. Introduction Community
More informationIssues concerning the Court of Justice
Issues concerning the Court of Justice Catherine Barnard, Trinity College Cambridge The need for a dispute settlement procedure The issue Pending procedures Body to rule on interpretation of the withdrawal
More informationEuropean Ombudsman. Emily O'Reilly. European Ombudsman. Mr Peter Gøtzsche. Strasbourg, 26/06/2017. Complaint 1475/2016/JAS
European Ombudsman Emily O'Reilly European Ombudsman Mr Peter Gøtzsche E-mail: pcg@cochrane.dk Strasbourg, 26/06/2017 Complaint 1475/2016/JAS Dear Mr Gøtzsche, I write in relation to your complaint 1475/2016/JAS
More informationMadam Chair, Ladies and gentlemen, Members of the European Parliament,
Presentation of the priorities of the Bulgarian Presidency of the Council of the EU in the area of health before the Environment, Public Health and Food Safety Committee of the European Parliament Kiril
More informationEuropean Medicines Agency decision
EMA/519145/2014 European Medicines Agency decision P/0235/2014 of 8 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver
More informationEuropean Medicines Agency decision
EMA/781916/2015 European Medicines Agency decision P/0315/2015 of 21 December 2015 on the agreement of a paediatric investigation plan and on the granting of a waiver for ethosuximide (EMEA-001617-PIP01-14)
More informationStandard Operating Procedure for Disagreement in procedures Referral Art. 33(1) to CMDv
Standard Operating Procedure for Disagreement in procedures Referral Art. 33(1) to CMDv Edition number: 03 Edition date: 12/11/09 Implementation date: 01/01/2010 EDITI ON DATE Page/secti on REASON FOR
More informationEuropean Medicines Agency decision
EMA/528123/2014 European Medicines Agency decision P/0252/2014 of 30 September 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver
More informationSUBMISSION OF COMMENTS ON
SUBMISSION OF COMMENTS ON: draft revision 3 of Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of
More informationEUROPEAN MEDICINES AGENCY DECISION. of 8 March 2010
European Medicines Agency Doc. Ref. EMA/123304/2010 P/29/2010 EUROPEAN MEDICINES AGENCY DECISION of 8 March 2010 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and
More informationEuropean Medicines Agency decision
EMA/802406/2010 European Medicines Agency decision P/289/2010 of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationMandate, objectives and rules of procedure
18 February 2014 EMA/INS/GMP/414260/2013 GMP/GDP inspectors working group (GMDP IWG) 1. General considerations In 1981 the European Commission established the Working Party on Control of Medicinal Products
More informationEuropean Medicines Agency decision
EMA/683319/2010 European Medicines Agency decision P/307/2010 of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationTerms of Reference and Rules of Procedure Health Products Regulatory Authority
Terms of Reference and Rules of Procedure Health Products Regulatory Authority MGT-P0007-16 7 JUNE 2018 CONTENTS 1 ESTABLISHMENT 3 2 MANDATE 3 3 COMPOSITION 6 4 CHAIRPERSON 6 5 SECRETARY TO THE AUTHORITY
More informationEuropean Medicines Agency decision
EMA/392211/2014 European Medicines Agency decision P/0195/2014 of 8 August 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/826074/2011 European Medicines Agency decision P/245/2011 of 21 October 2011 on the agreement of a paediatric investigation plan and on the granting of a waiver for furosemide (EMEA-000982-PIP01-10)
More informationCoordination group for Mutual recognition and Decentralised procedures (veterinary) RULES OF PROCEDURE
CMDv ROP-001-01 EMA/CMDv/37111/2011 London, 15 September 2011 Coordination group for Mutual recognition and Decentralised procedures (veterinary) RULES OF PROCEDURE Article 31 of Directive 2001/82/EC of
More informationEuropean Medicines Agency decision
EMA/85747/2013 European Medicines Agency decision P/0055/2013 of 25 March 2013 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/475432/2012 European Medicines Agency decision P/0163/2012 of 23 July 2012 on the agreement of a paediatric investigation plan and on the granting of a waiver for misoprostol (EMEA-001159-PIP02-12)
More informationSTANDARD OPERATING PROCEDURE. Amendments
Research Department STANDARD OPERATING PROCEDURE SOP History A104 Protocol v3.3, 05 March 2008 B126 Protocol Amendment Review v1.2, 05 March 2008 SOP Number C105 Created STH Research Department (AP & TJL)
More informationEuropean Medicines Agency decision
EMA/4029/2017 European Medicines Agency decision P/0370/2016 of 4 January 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/683356/2010 European Medicines Agency decision P/271/2010 of 3 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationEuropean Medicines Agency decision
EMA/86511/2015 European Medicines Agency decision P/0047/2015 of 6 March 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for efinaconazole
More informationContract 2007/ IPA Transition Assistance Programme. First Progress Report. European Commission
European Medicines Agency Communications and Networking London, 7 April 2008 Doc. Ref. EMEA/180416/2008 Contract 2007/146-691 IPA Transition Assistance Programme First Progress Report to the European Commission
More informationEuropean Medicines Agency decision
EMA/771133/2017 European Medicines Agency decision P/0397/2017 of 19 December 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2008R1234 EN 04.08.2013 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COMMISSION REGULATION (EC) No 1234/2008 of 24
More informationCMDv/BPG/018. BEST PRACTICE GUIDE for Worksharing. Edition number: 03. Edition date: 16 May Implementation date: 01 January 2010
EMA/CMDv/75429/2009 BEST PRACTICE GUIDE for Worksharing Edition number: 03 Edition date: 16 May 2013 Implementation date: 01 January 2010 CMDv Secretariat: 7 Westferry Circus, Canary Wharf, London, E14
More informationEuropean Medicines Agency decision
EMA/716686/2010 European Medicines Agency decision P/266/2010 of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationQuestions and Answers (Q&As) on the External Guidance of Policy 0070 on Clinical Data Publication (CDP)
20 September 2017 EMA/14227/2017 Rev. 1 Documents Access and Publication Service Office of the Deputy Executive Director Questions and Answers (Q&As) on the External Guidance of Policy 0070 on Clinical
More informationMemorandum of understanding on working arrangements
26 January 2012 Memorandum of understanding on working arrangements between the European Medicines Agency and the European Food Safety Authority THE EUROPEAN MEDICINES AGENCY AND THE EUROPEAN FOOD SAFETY
More informationProcedural advice to applicants/marketing authorisation holders on re-examination of CVMP opinions
9 November 2017 EMA/CVMP/321528/2017 Committee for Medicinal Products for Veterinary Use Procedural advice to applicants/marketing authorisation holders on re-examination of 1. Introduction Re-examination
More informationOpinion 3/2019 concerning the Questions and Answers on the interplay between the Clinical Trials Regulation (CTR) and the General Data Protection
Opinion 3/2019 concerning the Questions and Answers on the interplay between the Clinical Trials Regulation (CTR) and the General Data Protection regulation (GDPR) (art. 70.1.b)) Adopted on 23 January
More informationEuropean Medicines Agency decision
EMA/519929/2014 European Medicines Agency decision P/0255/2014 of 30 September 2014 on the agreement of a paediatric investigation plan and on the granting of a waiver for ibuprofen (sodium dihydrate),
More informationGUIDANCE for Exchange of documentation relating to a RVMP between MS
EMEA/CMDv/126637/2006 GUIDANCE for Exchange of documentation relating to a RVMP between MS Edition number: 03 Edition date: 7 December 2014 Implementation date: 1 December 2014 EDITION DATE PAGE/S REASON
More informationDoc. Ref: CMDh/001/2001 Draft Revision 4, October Introduction
RECOMMENDATIONS FOR MUTUAL RECOGNITION PROCEDURE AFTER FINALISATION OF AN ARBITRATION PROCEDURE WITH A POSITIVE OPINION BY THE CPMP AND A POSITIVE DECISION BY THE ECEU COMMISSION Introduction Doc. Ref:
More informationEuropean action. Counterfeit, legislation, crime, Moscow Declaration, multiscetoral, consensus
focus 2 European action against counterfeit medicines Author Dr Rolf Einbeck, Institute for Statistics and International Registrations, Holzkirchen, Germany einbeck@isir.de Key words Counterfeit, legislation,
More informationEuropean Medicines Agency decision
EMA/757737/2010 European Medicines Agency decision P/306/2010 of 22 December 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationHaving regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
DIRECTIVE 75/319/EEC Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ No L 147 of
More informationEuropean Medicines Agency decision
EMA/102436/2018 European Medicines Agency decision P/0070/2018 of 16 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationConsultation draft 31 March, 2005
APPENDIX 5 Draft Regulation EC 882/2004 on official controls performed to ensure the verification of compliance with feed and food law, animal health and animal welfare rules Guidance Notes for enforcement
More informationPatient Information and Consent
Version 1.4 Effective date: 31 October 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.4 31 October 2012 Version 1.3 22 August
More informationBy-Laws of the European League against Rheumatism
By-Laws of the European League against Rheumatism Article 1 Name, domicile, legal stipulations Article 2 Objectives of EULAR Article 3 Membership Article 4 Funds Article 5 Organisational structure of EULAR
More informationAmendments to Healthcare Research
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationEUROPEAN MEDICINES AGENCY DECISION. of 23 December 2009
European Medicines Agency Doc. Ref. EMA/837966/2009 P/266/2009 EUROPEAN MEDICINES AGENCY DECISION of 23 December 2009 on the agreement of a Paediatric Investigation Plan and on the granting of a deferral
More informationEuropean Medicines Agency decision
EMA/58370/2014 European Medicines Agency decision P/0047/2014 of 11 March 2014 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationPHARMACEUTICAL COMMITTEE
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations PHARM 466 PHARMACEUTICAL
More informationBy-Laws of the European League against Rheumatism
By-Laws of the European League against Rheumatism Article 1 Name, domicile, legal stipulations Article 2 Objectives of EULAR Article 3 Membership Article 4 Funds Article 5 Organisational structure of EULAR
More informationJOB DESCRIPTION. Multi Systemic Therapy Supervisor. 37 hours per week + on call responsibilities. Cambridgeshire MST service JOB FUNCTION
JOB DESCRIPTION Multi Systemic Therapy Supervisor JOB TITLE: LOCATION: GRADE: HOURS: SERVICE: ACCOUNTABLE TO: MST Supervisor Cambridgeshire Grade 8 b 37 hours per week + on call responsibilities Cambridgeshire
More informationThe Reform of EU State Aid Control
EEA Annual Conference Amsterdam August 26th, 2005 The Reform of EU State Aid Control Lars-Hendrik Röller * Chief Economist DG COMP, European Commission *The views expressed are those of the author and
More informationDEFINITIONS. May be written into the law, or based on court decisions.
DEFINITIONS Research (Experimental Use) Exemption A provision that certain actions which fall within the claims of a granted patent are not patent infringement if they are done for the purposes of research.
More informationEuropean Medicines Agency decision
EMA/335351/2010 European Medicines Agency decision P/90/2010 of 1 June 2010 on the agreement of a paediatric investigation plan and on the granting of a waiver for bisoctrizole / titanium dioxide (EMEA-000585-PIP01-09)
More informationThe Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005
STATUTORY INSTRUMENTS 2005 No. 2750 MEDICINES The Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005 Made - - - - - 6th October 2005 Laid before Parliament 7th October 2005
More informationCHAPTER 7 CMDh BEST PRACTICE GUIDE ON WORKSHARING Doc. Ref.: CMDh/297/2013/Rev.2021 AprilOctober 2013
1. INTRODUCTION CHAPTER 7 CMDh BEST PRACTICE GUIDE ON WORKSHARING Doc. Ref.: CMDh/297/2013/Rev.2021 AprilOctober 2013 Article 20 of Commission Regulation (EC) No 1234/2008 of 24 November 2008 as amended
More informationJUDGMENT OF THE COURT OF FIRST INSTANCE (Second Chamber, Extended Composition) 28 January 2003 *
JUDGMENT OF THE COURT OF FIRST INSTANCE (Second Chamber, Extended Composition) 28 January 2003 * In Case T-147/00, Les Laboratoires Servier, established in Neuilly-sur-Seine (France), represented by C.
More informationEX-EMPLOYEE v GEDEON RICHTER
CASE AUTH/2575/2/13 EX-EMPLOYEE v GEDEON RICHTER Promotion of Esmya An ex-employee of Preglem (a wholly owned subsidiary of Gedeon Richter) complained prospectively about the promotion of Esmya (ulipristal
More informationTHIS IS AN UNOFFICIAL TRANSLATION OF CIRCULAR LETTER XXX PUBLISHED IN DUTCH / FRENCH.
THIS IS AN UNOFFICIAL TRANSLATION OF CIRCULAR LETTER XXX PUBLISHED IN DUTCH / FRENCH. Dear Madame, Dear Sir, This document is intended to update information about submission of applications for clinical
More informationIBC s 20 th Conference on. Paediatric Extensions Issues and Challenges. Christopher Stothers 22 February 2012
IBC s 20 th Conference on Biotech & Pharmaceutical Patenting 2012 Paediatric Extensions Issues and Challenges Christopher Stothers 22 February 2012 1 Overview of this Session Problem/Solution Opportunity/Threats
More informationWhat does GLP mean in regulated Bioanalysis or Biomarker Bioanalysis
What does GLP mean in regulated Bioanalysis or Biomarker Bioanalysis Philip Timmerman, on behalf of the EBF EBF 9 th Open Symposium 16-18 November 2016 Barcelona Theme of today Plasma samples will be analyzed
More informationEuropean Medicines Agency decision
EMA/670696/2010 European Medicines Agency decision P/259/2010 of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationCOMMERCIAL LICENSING REGULATIONS 2015 (CONDITIONS OF LICENCE) RULES 2015
COMMERCIAL LICENSING REGULATIONS 2015 (CONDITIONS OF LICENCE) RULES 2015 Date of Adoption: 12 April 2015 The Board of Directors of the Abu Dhabi Global Market, in implementation of section 10(1) of the
More informationIndex A R T I C L E S O F A S S O C I A T I O N
Approved by the Assembly on May 31, 2017 I N T E R N A T I O N A L C O U N C I L F O R H A R M O N I S A T I O N O F T E C H N I C A L R E Q U I R E M E N T S F O R P H A R M A C E U T I C A L S F O R
More informationClinical Research Services
Jeevan Scientific Technology Limited a symbol of quality and diverse solutions Clinical Research Services JEEVAN SCIENTIFIC TECHNOLOGY LIMITED Jeevan Scientific is an Independent Contract Research Organization,
More informationArticle 1 General principles and objectives
NOTE: The EU reserves the right to make subsequent modifications to this text and to complement it at a later stage, by modifying, supplementing or withdrawing all, or any part, at any time. The relationship
More informationHealth Care Reform Workshop Ukraine 16 and 17 May 2017 Kyiv Ukrainian Health Trade Unions; ITUC; PERC; ILO; EPSUX X Relevant EU norms and regulations
Health Care Reform Workshop Ukraine 16 and 17 May 2017 Kyiv Ukrainian Health Trade Unions; ITUC; PERC; ILO; EPSUX X Relevant EU norms and regulations in the context of the Association Agreement Ukraine-European
More informationConstitution - Article 1
NAME, MISSION AND PRINCIPLES Constitution - Article 1 1.1 Name This network shall be known as the European Huntington s Disease Network and referred to in this Constitution as EHDN. 1.2. Mission EHDN aims
More informationEuropean Medicines Agency decision
EMA/253504/2017 European Medicines Agency decision P/0125/2017 of 5 May 2017 on the granting of a product specific waiver for ramipril / indapamide (EMEA-002081-PIP01-16) in accordance with Regulation
More informationEuropean Medicines Agency decision
EMA/130187/2012 European Medicines Agency decision P/0043/2012 of 28 February 2012 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver
More informationOfficial Journal of the European Union L 334/7
12.12.2008 Official Journal of the European Union L 334/7 COMMISSION REGULATION (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for
More informationEuropean Medicines Agency decision
EMA/215073/2015 European Medicines Agency decision P/0085/2015 of 8 May 2015 on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M07)
More informationEuropean Medicines Agency decision
EMA/624577/2015 P/0261/2015 of 30 October 2015 on the granting of a product specific waiver for mogamulizumab (EMEA-001816-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament
More informationExperiences of European countries with health workforce migration
Experiences of European countries with health workforce migration Implementation of the WHO Global Code of Practice on the International Recruitment of Health Personnel and applicability of its principles
More information13667/14 ADD 1 MH/mk 1 DG B 4A
Council of the European Union Brussels, 6 October 2014 Interinstitutional File: 2014/0124 (COD) 13667/14 ADD 1 SOC 653 EMPL 115 JAI 712 MIGR 128 ECOFIN 855 COMPET 543 CODEC 1891 REPORT from: Permanent
More informationEuropean Medicines Agency decision
EMA/479450/2016 European Medicines Agency decision P/0199/2016 of 18 July 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral for andexanet alfa (EMEA-001902-PIP01-15)
More informationSTATUTORY INSTRUMENT. S.I. No. 786 of EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007
STATUTORY INSTRUMENT S.I. No. 786 of 2007 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (Prn. A7/2179) 2 [786] S.I. No. 786 of 2007 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS
More informationEuropean Medicines Agency decision
EMA/249209/2010 European Medicines Agency decision P/75/2010 of 5 May 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for levonorgestrel
More informationEuropean Medicines Agency decision
EMA/249985/2011 P/83/2011 of 6 April 2011 on the refusal of a product specific waiver for aciclovir (EMEA-001066-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and
More information2. SPECIFIC COMMENTS ON TEXT
SUBMISSION OF COMMENTS ON THE Detailed guidance for the request for authorization of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Amendments to Active Research Studies SOP-RES-024 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018
More informationJUDGMENT OF THE COURT OF FIRST INSTANCE (Fifth Chamber) 18 December 2003 *
FERN OLIVIERI v COMMISSION AND EMEA JUDGMENT OF THE COURT OF FIRST INSTANCE (Fifth Chamber) 18 December 2003 * In Case T-326/99, Nancy Fern Olivieri, resident in Toronto (Canada), represented by N. Green
More informationEUROPEAN MEDICINES AGENCY DECISION. of 29 February 2008
European Medicines Agency Doc. Ref. EMEA/96630/2008 P/9/2008 EUROPEAN MEDICINES AGENCY DECISION of 29 February 2008 on the application for agreement of a Paediatric Investigation Plan for Cozaar and associated
More information